September 10th 2020
Luciano J. Costa, MD, PhD, discusses emerging data regarding the use of BCMA-directed bispecific antibodies and antibody-drug conjugates in multiple myeloma.
September 9th 2020
The first-in-class radioiodinated phospholipid drug conjugate CLR 131 elicited a clinically meaningful overall response rate of 40% in patients with triple-class refractory multiple myeloma who received a total administered dose of 60 mCi or greater.
September 8th 2020
Marc J. Braunstein, MD, PhD, highlights pivotal research on the use of triplet and quadruplet regimens in the up-front and relapsed/refractory multiple myeloma treatment settings presented during the 2020 ASCO Virtual Scientific Program.
Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
September 3rd 2020
Nina Shah, MD, discusses the phase 1/2 EVOLVE study with orvacabtagene autoleucel in relapsed/refractory multiple myeloma.
September 2nd 2020
Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma.
September 1st 2020
Katja Weisel, MD, explains the rationale for the GMMG-CONCEPT trial, details the key interim findings, and provides foresight on future milestones in the field of multiple myeloma.
Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.
The overall response rates with subcutaneous daratumumab proved to be similar to that of the intravenous formulation of the drug irrespective of body weight.
